MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price shot up 5.8% on Tuesday . The stock traded as high as $6.05 and last traded at $6.03. 4,183 shares were traded during mid-day trading, a decline of 99% from the average session volume of 580,017 shares. The stock had previously closed at $5.70.
Analyst Ratings Changes
Separately, BTIG Research lifted their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Sunday, August 14th.Get MaxCyte alerts:
MaxCyte Stock Performance
The firm has a market cap of $621.33 million, a price-to-earnings ratio of -30.50 and a beta of 1.17. The stock's 50 day simple moving average is $5.60.
Insider Buying and Selling at MaxCyteIn other MaxCyte news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction on Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the completion of the sale, the insider now owns 10,735,786 shares in the company, valued at approximately $46,163,879.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.11% of the stock is currently owned by company insiders.
Institutional Trading of MaxCyte
Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of MaxCyte in the 2nd quarter worth $27,000. Freemont Management S.A. purchased a new stake in MaxCyte during the first quarter valued at about $68,000. Nkcfo LLC purchased a new stake in MaxCyte during the first quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Finally, PDT Partners LLC purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Institutional investors own 66.40% of the company's stock.
MaxCyte Company Profile
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.